Dysport
Drug
Ipsen Innovation
Total Payments
$16.6M
Transactions
21,420
Doctors
3,959
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.4M | 10,494 | 1,802 |
| 2023 | $4.1M | 5,498 | 1,640 |
| 2020 | $495.05 | 11 | 10 |
| 2019 | $2,148 | 126 | 95 |
| 2018 | $4.1M | 4,890 | 1,384 |
| 2017 | $23,371 | 401 | 303 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.3M | 9,084 | 79.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 461 | 10.4% |
| Travel and Lodging | $454,683 | 855 | 2.7% |
| Consulting Fee | $434,733 | 103 | 2.6% |
| Food and Beverage | $397,147 | 10,791 | 2.4% |
| Honoraria | $190,883 | 59 | 1.1% |
| Education | $65,365 | 32 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $64,150 | 33 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,843 | 2 | 0.1% |
Payments by Type
Research
$13.3M
9,084 transactions
General
$3.4M
12,336 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | Ipsen Pharma SAS | $4.4M | 0 |
| Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | Ipsen Innovation | $2.2M | 3 |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | Ipsen Innovation | $1.9M | 2 |
| A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | Ipsen Innovation | $769,281 | 0 |
| A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT Used In The Treatment Of Upper Limb Spasticity In Children | Ipsen Innovation | $749,483 | 0 |
| A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults | Ipsen Pharma SAS | $594,121 | 0 |
| A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | Ipsen Pharma SAS | $470,655 | 0 |
| A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity | Ipsen Pharma SAS | $389,988 | 0 |
| A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinumtoxinA in Paediatric Lower Limb Spasticity. | Ipsen Biopharmaceuticals, Inc | $349,603 | 1 |
| A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinumtoxinA in Paediatric Lower Limb Spasticity | Ipsen Biopharmaceuticals, Inc | $226,295 | 1 |
| A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus | Ipsen Innovation | $133,244 | 2 |
| An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements ofAbobotulinumtoxinA1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis | Ipsen Pharma SAS | $126,627 | 0 |
| A Prospective, Open Label, Single Center Study ofPatientsWith Multiple Sclerosis WithLower Extremity SpasticityWho AreTreatedWithDysport | Ipsen Biopharmaceuticals, Inc | $104,392 | 0 |
| Ipsen Harvard Catalyst | Ipsen Bioscience Inc | $100,000 | 0 |
| A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus | Ipsen Bioscience Inc | $80,494 | 0 |
| A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients | Ipsen Innovation | $66,003 | 0 |
| An International, Multicentre, Observational, Prospective, Longitudinal Cohort Study to Assess the Impact of Integrated Upper Limb Spasticity Management Including the Use of BoNT-A- Injections on Patient-centred Goal Attainment in Real Life Practice | Ipsen Biopharmaceuticals, Inc | $60,067 | 0 |
| Predicting Post Stroke Limb Spasticity | Ipsen Biopharmaceuticals, Inc | $56,600 | 0 |
| Effect of Single Event Multi Level Chemoneurolysis With Dysport on Energy Expenditure and Walking Efficiency | Ipsen Biopharmaceuticals, Inc | $50,760 | 0 |
| International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh) | Ipsen Pharma SAS | $46,294 | 0 |
Top Doctors Receiving Payments for Dysport
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Daniel Cusator | — | Anaheim, CA | $13.2M | 8,968 |
| , M.D | Physical Medicine & Rehabilitation | Houston, TX | $212,326 | 131 |
| , M.D | Physical Medicine & Rehabilitation | Overland Park, KS | $181,700 | 130 |
| , M.D | Emergency Medical Services | Austin, TX | $168,959 | 153 |
| , MD | Physical Medicine & Rehabilitation | Elkins Park, PA | $157,151 | 99 |
| , MD | Neurology | Fullerton, CA | $154,975 | 121 |
| , D.O, | Neurology | Washington, DC | $122,531 | 88 |
| , DO | Pain Medicine | Oak Lawn, IL | $114,085 | 97 |
| , M.D | Physical Medicine & Rehabilitation | Milwaukee, WI | $91,248 | 71 |
| , M.D | Neurology | Southfield, MI | $91,187 | 69 |
| , M.D | Neurology | Loma Linda, CA | $82,052 | 64 |
| , D.O | Neurology | Farmington Hills, MI | $81,688 | 52 |
| , MD | Pediatric Rehabilitation Medicine | Milwaukee, WI | $76,172 | 56 |
| , MD | Pediatric Rehabilitation Medicine | Atlanta, GA | $67,157 | 62 |
| , MD | Neurology | Omaha, NE | $58,093 | 47 |
| , MD | Physical Medicine & Rehabilitation | Philadelphia, PA | $57,311 | 23 |
| , MD | Physical Medicine & Rehabilitation | Saint Paul, MN | $54,028 | 41 |
| , MD | Neurology with Special Qualifications in Child Neurology | New Orleans, LA | $53,443 | 43 |
| , MD | Physical Medicine & Rehabilitation | Marrero, LA | $52,917 | 73 |
| , M.D | Neurology | Dallas, TX | $51,503 | 32 |
| , M.D | Spinal Cord Injury Medicine | Downey, CA | $47,570 | 50 |
| , M.D | Physical Medicine & Rehabilitation | Farmington Hills, MI | $46,168 | 121 |
| , MD | Physical Medicine & Rehabilitation | Slc, UT | $37,995 | 49 |
| , MD | Neurological Surgery | Nashville, TN | $37,375 | 35 |
| , MD | Neurology | Los Angeles, CA | $36,951 | 30 |
Ad
Manufacturing Companies
- Ipsen Innovation $6.4M
- Ipsen Pharma SAS $6.2M
- Ipsen Biopharmaceuticals, Inc $3.8M
- Ipsen Bioscience Inc $189,294
- Saol Therapeutics Inc. $12,318
- Ipsen Biopharm Limited $6,664
Product Information
- Type Drug
- Total Payments $16.6M
- Total Doctors 3,959
- Transactions 21,420
About Dysport
Dysport is a drug associated with $16.6M in payments to 3,959 healthcare providers, recorded across 21,420 transactions in the CMS Open Payments database. The primary manufacturer is Ipsen Innovation.
Payment data is available from 2017 to 2024. In 2024, $8.4M was paid across 10,494 transactions to 1,802 doctors.
The most common payment nature for Dysport is "Unspecified" ($13.3M, 79.8% of total).
Dysport is associated with 20 research studies, including "A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity" ($4.4M).